- Home
- PHVS vs ESRT Comparison
PHVS vs ESRT Comparison
Compare PHVS & ESRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHVS
- ESRT
- Stock Information
- Founded
- PHVS 2015
- ESRT 2011
- Country
- PHVS Switzerland
- ESRT United States
- Employees
- PHVS N/A
- ESRT N/A
- Industry
- PHVS Biotechnology: Pharmaceutical Preparations
- ESRT Real Estate Investment Trusts
- Sector
- PHVS Health Care
- ESRT Real Estate
- Exchange
- PHVS Nasdaq
- ESRT Nasdaq
- Market Cap
- PHVS 1.3B
- ESRT 1.2B
- IPO Year
- PHVS 2021
- ESRT 2013
- Fundamental
- Price
- PHVS $24.30
- ESRT $7.58
- Analyst Decision
- PHVS Strong Buy
- ESRT Hold
- Analyst Count
- PHVS 5
- ESRT 2
- Target Price
- PHVS $35.60
- ESRT $10.65
- AVG Volume (30 Days)
- PHVS 123.2K
- ESRT 1.2M
- Earning Date
- PHVS 11-12-2025
- ESRT 10-29-2025
- Dividend Yield
- PHVS N/A
- ESRT 1.85%
- EPS Growth
- PHVS N/A
- ESRT N/A
- EPS
- PHVS N/A
- ESRT 0.24
- Revenue
- PHVS N/A
- ESRT $763,746,000.00
- Revenue This Year
- PHVS N/A
- ESRT $2.27
- Revenue Next Year
- PHVS N/A
- ESRT $3.04
- P/E Ratio
- PHVS N/A
- ESRT $31.69
- Revenue Growth
- PHVS N/A
- ESRT 1.14
- 52 Week Low
- PHVS $11.51
- ESRT $6.56
- 52 Week High
- PHVS $26.33
- ESRT $11.62
- Technical
- Relative Strength Index (RSI)
- PHVS 59.77
- ESRT 47.88
- Support Level
- PHVS $23.20
- ESRT $7.50
- Resistance Level
- PHVS $24.75
- ESRT $7.95
- Average True Range (ATR)
- PHVS 1.29
- ESRT 0.19
- MACD
- PHVS 0.07
- ESRT -0.02
- Stochastic Oscillator
- PHVS 84.81
- ESRT 16.95
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.
About ESRT Empire State Realty Trust Inc.
Empire State Realty Trust operates as a pure-play greater New York and Manhattan-focused REIT, featuring its landmark Empire State Building office and observation deck. The company owns and operates around 8.5 million square feet of office space, about 80% of which is located in Manhattan.